NASDAQ:KDNY - Chinook Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $30.75
  • Forecasted Upside: 119.64 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$14.00
▲ +0.31 (2.26%)
1 month | 3 months | 12 months
Get New Chinook Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for KDNY and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for KDNY

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
$30.75
▲ +119.64% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Chinook Therapeutics in the last 3 months. The average price target is $30.75, with a high forecast of $38.00 and a low forecast of $25.00. The average price target represents a 119.64% upside from the last price of $14.00.
Buy
The current consensus among 5 polled investment analysts is to buy stock in Chinook Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/8/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/6/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
12/5/2019
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
3/4/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
6/2/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/31/2020
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/30/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
11/16/2020HC WainwrightInitiated CoverageBuy$28.00High
i
Rating by E. Arce at HC Wainwright
11/2/2020Evercore ISIInitiated CoverageOutperform$32.00Medium
i
10/20/2020OppenheimerUpgradeMarket Perform ➝ Outperform$25.00High
i
10/7/2020SVB LeerinkInitiated CoverageOutperform$38.00High
i
Rating by J. Schwartz at SVB Leerink LLC
10/6/2020William BlairReiterated RatingOutperformHigh
i
Rating by M. Phipps at William Blair
(Data available from 11/29/2015 forward)
Chinook Therapeutics logo
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, an investigational Phase III ready endothelin receptor antagonist for the treatment of IgA nephropathy and other primary glomerular diseases. Its product candidates include BION-1301, an investigational anti-APRIL monoclonal antibody is being evaluated in a Phase Ib trial for IgA nephropathy; and CHK-336, a preclinical development candidate for an undisclosed ultra-orphan kidney disease, as well as research programs for other rare, severe chronic kidney diseases, including polycystic kidney disease. Chinook Therapeutics, Inc. is based in Seattle, Washington.
Read More

Today's Range

Now: $14.00
$13.68
$14.15

50 Day Range

MA: $14.73
$11.90
$17.60

52 Week Range

Now: $14.00
$4.90
$20.20

Volume

79,546 shs

Average Volume

155,461 shs

Market Capitalization

$590.21 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.12